Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Revvity

What You Need to Know Ahead of Revvity’s Earnings Release

As Revvity gears up to reveal its second-quarter earnings report soon, analysts forecast single-digit profit growth.

Barchart

Is Revvity Stock Underperforming the Nasdaq?

Revvity has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Is Revvity Stock Underperforming the S&P 500?

Revvity has lagged the broader S&P 500 over the past year, though analysts maintain a cautiously positive outlook on its forward growth potential.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Do Wall Street Analysts Like Revvity Stock?

Although Revvity has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

What to Expect From Revvity’s Q4 2025 Earnings Report

Revvity is set to announce its fourth-quarter results soon, and analysts expect a single-digit rise in its adjusted earnings per share.

Barchart

How Is Revvity's Stock Performance Compared to Other Health Care Stocks?

Revvity has underperformed the Health Care industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Revvity, Inc. (NYSE:RVTY) announced mixed third-quarter 2025 financial results on Monday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Revvity Lifts Profit Outlook, Launches $1 Billion Buyback Plan

Revvity, Inc. (NYSE:RVTY) announced its third-quarter 2025 financial results on Monday. The company’s performance was mixed compared to analyst expectations, and the stock declined immediately.

Benzinga

Here's What to Expect From Revvity's Next Earnings Report

Healthcare major Revvity is set to announce its third-quarter results in the upcoming weeks, and analysts expect a notable double-digit drop in earnings.

Barchart

Revvity Stock: Is RVTY Underperforming the Healthcare Sector?

Despite Revvity’s weak performance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Revvity Stock Will Climb or Sink?

Diagnostics company Revvity has been underperforming the broader market. Are analysts still bullish about its stock?

Barchart

Revvity Slashes Outlook As China Policy Deals Diagnostics Blow

Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025.

Benzinga

Earnings Preview: What to Expect From Revvity's Report

Revvity is all set to release its fiscal second-quarter earnings later this month, and analysts project a single-digit earnings decline.

Barchart

Is Wall Street Bullish or Bearish on Revvity Stock?

Although Revvity has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Revvity’s Quarterly Earnings Preview: What You Need to Know

Revvity is gearing up to announce its first-quarter results later this month, and analysts expect a single-digit drop in earnings.

Barchart

Is Revvity Stock Underperforming the Nasdaq?

Despite lagging behind the Nasdaq Composite over the past year, analysts remain bullish on Revvity’s prospects.

Barchart

Are Wall Street Analysts Bullish on Revvity Stock?

Revvity has lagged behind the broader market this year, and Wall Street analysts maintain a cautiously optimistic outlook on its future potential.

Barchart

Is Revvity Stock Underperforming the S&P 500?

Revvity has substantially lagged behind the S&P 500 over the past year, yet analysts remain bullish on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

What Are Wall Street Analysts' Target Price for Revvity Stock?

Revvity has underperformed the broader market this year, but Wall Street analysts remain somewhat optimistic about the stock's future prospects.

Barchart

Revvity Earnings Preview: What to Expect

Revvity is set to release its third-quarter earnings next month, with analysts projecting a slight decline in profit.

Barchart

How Is Revvity's Stock Performance Compared to Other Diagnostics & Research Stocks?

Despite Revvity’s underperformance compared to its industry peers over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Revvity Stock: Is Wall Street Bullish or Bearish?

Revvity has significantly underperformed the broader market this year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

What You Need to Know Ahead of Revvity’s Earnings Release

Revvity will release its second-quarter earnings later this month, and analysts anticipate a single-digit profit dip.

Barchart

Stocks Finish Mostly Lower as Higher Bond Yields Undercut Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. Stocks on Thursday settled mixed, with the S&P...

Birmingham Post

Revenues and profits rise at Immunodiagnostic Systems in year after £110m takeover

The Boldon company became part of American life sciences group Revvity two years ago

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Petroleum

1,179 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.